Vista Pharmaceuticals Ltd
Incorporated in 1992, Vista Pharmaceuticals
Ltd manufactures and sells pharmaceutical, medical and veterinary preparations[1]
- Market Cap ₹ 46.4 Cr.
- Current Price ₹ 7.54
- High / Low ₹ 12.0 / 5.71
- Stock P/E
- Book Value ₹ 5.92
- Dividend Yield 0.00 %
- ROCE -30.3 %
- ROE -29.5 %
- Face Value ₹ 2.00
Pros
- Debtor days have improved from 347 to 21.6 days.
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 21.2%
- Company has a low return on equity of -17.1% over last 3 years.
- Promoter holding has decreased over last 3 years: -14.2%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14 | 15 | 24 | 29 | 31 | 23 | 1 | 0 | 1 | 10 | 10 | 5 | |
| 11 | 13 | 21 | 24 | 30 | 28 | 3 | 2 | 5 | 13 | 14 | 20 | |
| Operating Profit | 3 | 3 | 3 | 5 | 1 | -5 | -2 | -1 | -4 | -3 | -4 | -15 |
| OPM % | 20% | 17% | 13% | 18% | 4% | -21% | -136% | -326% | -432% | -33% | -41% | -271% |
| 0 | 0 | 0 | 0 | 3 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 0 | 1 | 1 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Profit before tax | 1 | 1 | 1 | 3 | 1 | -4 | -4 | -3 | -6 | -5 | -5 | -16 |
| Tax % | -9% | 8% | -2% | 23% | 18% | -7% | -47% | -66% | -4% | -13% | -12% | -25% |
| 1 | 1 | 1 | 2 | 1 | -4 | -2 | -1 | -6 | -5 | -5 | -12 | |
| EPS in Rs | 0.11 | 0.06 | 0.47 | 0.75 | 0.31 | -1.21 | -0.55 | -0.24 | -1.54 | -1.23 | -1.26 | -1.96 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -10% |
| 5 Years: | 34% |
| 3 Years: | 75% |
| TTM: | -45% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -159% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | -8% |
| 3 Years: | -5% |
| 1 Year: | -29% |
| Return on Equity | |
|---|---|
| 10 Years: | -9% |
| 5 Years: | -14% |
| 3 Years: | -17% |
| Last Year: | -29% |
Balance Sheet
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 6 | 6 | 6 | 7 | 7 | 8 | 9 | 12 | 12 |
| Reserves | 5 | 6 | 11 | 26 | 30 | 24 | 25 | 28 | 29 | 31 | 33 | 24 |
| 4 | 8 | 11 | 11 | 11 | 15 | 11 | 13 | 10 | 8 | 7 | 10 | |
| 8 | 7 | 14 | 10 | 6 | 6 | 9 | 8 | 9 | 10 | 7 | 9 | |
| Total Liabilities | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
| 11 | 10 | 13 | 18 | 21 | 21 | 20 | 19 | 20 | 19 | 19 | 18 | |
| CWIP | 0 | 0 | 2 | 7 | 9 | 9 | 9 | 9 | 9 | 10 | 10 | 11 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 12 | 16 | 26 | 28 | 24 | 22 | 24 | 27 | 27 | 29 | 31 | 26 | |
| Total Assets | 23 | 26 | 42 | 53 | 53 | 51 | 53 | 56 | 56 | 58 | 60 | 55 |
Cash Flows
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -4 | -2 | 3 | -5 | 3 | 1 | -7 | -1 | -2 | -5 | -7 | ||
| -0 | -0 | -4 | -11 | -6 | -2 | -0 | -0 | -1 | -1 | -0 | ||
| 4 | 3 | 6 | 11 | 1 | 0 | 7 | 1 | 3 | 6 | 8 | ||
| Net Cash Flow | 0 | 0 | 5 | -4 | -1 | -1 | -0 | -0 | 0 | -0 | 1 | |
| Free Cash Flow | -4 | -3 | -1 | -15 | -2 | -1 | -7 | -1 | -3 | -6 | -7 | |
| CFO/OP | -131% | -89% | 84% | -86% | 299% | -17% | 390% | 78% | 64% | 149% | 163% |
Ratios
Figures in Rs. Crores
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 300 | 231 | 136 | 137 | 98 | 165 | 624 | 9,789 | 4,106 | 515 | 505 | 22 |
| Inventory Days | 10 | 97 | 185 | 250 | 162 | 148 | 4,840 | 9,204 | 991 | 279 | 359 | 770 |
| Days Payable | 359 | 236 | 293 | 209 | 76 | 79 | 2,555 | 5,297 | 1,007 | 304 | 244 | 443 |
| Cash Conversion Cycle | -50 | 92 | 27 | 178 | 184 | 234 | 2,909 | 13,696 | 4,089 | 490 | 620 | 349 |
| Working Capital Days | -8 | 206 | 12 | 137 | 137 | 81 | 1,681 | 10,154 | 3,460 | 318 | 440 | -95 |
| ROCE % | 14% | 10% | 9% | 12% | 6% | -5% | -5% | -4% | -10% | -8% | -9% | -30% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Export Sales Revenue INR Lakhs |
|
|||||||||||
| Electricity Consumption KWH |
||||||||||||
| Number of Permanent Employees Count |
||||||||||||
| Net Capital Turnover Ratio Times |
||||||||||||
Extracted by Screener AI
Documents
Announcements
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
29 May - Vista Pharmaceuticals submitted FY2026 Annual Secretarial Compliance Report on 29 May 2026; no non-compliances noted.
- Outcome Of Board Meeting Under Regulations 30 Read With 33 (3) Of SEBI (LODR) Regulations, 2015 29 May
-
Board Meeting Intimation for Approval Of Audited Financial Results For The Quarter And Year Ended 31.03.2026
19 May - Board meeting on 29 May 2026 to consider audited FY2025-26 financial results and audit report.
-
Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2
29 Apr - Vista Pharmaceuticals confirms it is not a Large Corporate; FY2025-26 borrowing and debt issuance were nil.
- Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 14 Apr
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
a) The company offers over the counter & prescription generic drug products consisting of tablets, capsules and liquids covering various therapeutic categories and veterinary preparations
b) It manufactures pharmaceutical drugs such as sulphamethoxazole, trimethoprim
and isoxsuprime.
c) The company also sells its products to related companies (Common Directors) engaged in manufacturing formulations